Logo image of DSGN

DESIGN THERAPEUTICS INC (DSGN) Stock Fundamental Analysis

USA - NASDAQ:DSGN - US25056L1035 - Common Stock

6.64 USD
-0.04 (-0.6%)
Last: 10/29/2025, 2:03:36 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to DSGN. DSGN was compared to 534 industry peers in the Biotechnology industry. DSGN has a great financial health rating, but its profitability evaluates not so good. DSGN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DSGN has reported negative net income.
DSGN had a negative operating cash flow in the past year.
In the past 5 years DSGN always reported negative net income.
In the past 5 years DSGN always reported negative operating cash flow.
DSGN Yearly Net Income VS EBIT VS OCF VS FCFDSGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a decent Return On Assets value of -28.48%, DSGN is doing good in the industry, outperforming 69.10% of the companies in the same industry.
With a decent Return On Equity value of -29.80%, DSGN is doing good in the industry, outperforming 77.53% of the companies in the same industry.
Industry RankSector Rank
ROA -28.48%
ROE -29.8%
ROIC N/A
ROA(3y)-20.51%
ROA(5y)-18.66%
ROE(3y)-21.37%
ROE(5y)-19.56%
ROIC(3y)N/A
ROIC(5y)N/A
DSGN Yearly ROA, ROE, ROICDSGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

DSGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DSGN Yearly Profit, Operating, Gross MarginsDSGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for DSGN has been increased compared to 1 year ago.
DSGN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for DSGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DSGN Yearly Shares OutstandingDSGN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
DSGN Yearly Total Debt VS Total AssetsDSGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 21.54 indicates that DSGN is not in any danger for bankruptcy at the moment.
The Altman-Z score of DSGN (21.54) is better than 90.82% of its industry peers.
DSGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 21.54
ROIC/WACCN/A
WACCN/A
DSGN Yearly LT Debt VS Equity VS FCFDSGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

DSGN has a Current Ratio of 25.13. This indicates that DSGN is financially healthy and has no problem in meeting its short term obligations.
DSGN has a Current ratio of 25.13. This is amongst the best in the industry. DSGN outperforms 96.82% of its industry peers.
A Quick Ratio of 25.13 indicates that DSGN has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 25.13, DSGN belongs to the best of the industry, outperforming 96.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 25.13
Quick Ratio 25.13
DSGN Yearly Current Assets VS Current LiabilitesDSGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for DSGN have decreased strongly by -24.44% in the last year.
EPS 1Y (TTM)-24.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

DSGN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.52% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-54.93%
EPS Next 2Y-18.75%
EPS Next 3Y-17.88%
EPS Next 5Y-7.52%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DSGN Yearly Revenue VS EstimatesDSGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2028 2029 2030 2031 2032 200M 400M 600M
DSGN Yearly EPS VS EstimatesDSGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DSGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DSGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DSGN Price Earnings VS Forward Price EarningsDSGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DSGN Per share dataDSGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as DSGN's earnings are expected to decrease with -17.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18.75%
EPS Next 3Y-17.88%

More info and screens

0

5. Dividend

5.1 Amount

DSGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DESIGN THERAPEUTICS INC

NASDAQ:DSGN (10/29/2025, 2:03:36 PM)

6.64

-0.04 (-0.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners59.61%
Inst Owner Change-0.12%
Ins Owners2.03%
Ins Owner Change0%
Market Cap378.15M
Revenue(TTM)N/A
Net Income(TTM)-63488000
Analysts77.78
Price Target7.48 (12.65%)
Short Float %5.53%
Short Ratio10.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.78%
Min EPS beat(2)-8.54%
Max EPS beat(2)-1.01%
EPS beat(4)2
Avg EPS beat(4)2.39%
Min EPS beat(4)-8.54%
Max EPS beat(4)11.77%
EPS beat(8)6
Avg EPS beat(8)14.15%
EPS beat(12)9
Avg EPS beat(12)10.97%
EPS beat(16)10
Avg EPS beat(16)5.32%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.98%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.78
P/tB 1.78
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-1.24
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS0
BVpS3.74
TBVpS3.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.48%
ROE -29.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.51%
ROA(5y)-18.66%
ROE(3y)-21.37%
ROE(5y)-19.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.53%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 25.13
Quick Ratio 25.13
Altman-Z 21.54
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)109.7%
Cap/Depr(5y)462.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-61.9%
EPS Next Y-54.93%
EPS Next 2Y-18.75%
EPS Next 3Y-17.88%
EPS Next 5Y-7.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-68.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.41%
OCF growth 3YN/A
OCF growth 5YN/A

DESIGN THERAPEUTICS INC / DSGN FAQ

What is the ChartMill fundamental rating of DESIGN THERAPEUTICS INC (DSGN) stock?

ChartMill assigns a fundamental rating of 3 / 10 to DSGN.


What is the valuation status of DESIGN THERAPEUTICS INC (DSGN) stock?

ChartMill assigns a valuation rating of 0 / 10 to DESIGN THERAPEUTICS INC (DSGN). This can be considered as Overvalued.


How profitable is DESIGN THERAPEUTICS INC (DSGN) stock?

DESIGN THERAPEUTICS INC (DSGN) has a profitability rating of 1 / 10.


What is the earnings growth outlook for DESIGN THERAPEUTICS INC?

The Earnings per Share (EPS) of DESIGN THERAPEUTICS INC (DSGN) is expected to decline by -54.93% in the next year.